Particular features of the clinical course of the papilloma viral infection depending on quantitative indices of human papilloma viruses of a high carcinogenic risk
- Authors: Rakhmatulina M.R.1, Bolshenko N.V.2, Kuevda D.A.3, Trofimova O.B.3
-
Affiliations:
- State Research Center of Dermatovenereology and Cosmetology, Ministry of healthcare of the Russian Federation
- Russian Medical Academy of Postgraduate Studies, Ministry of Health Russian Federation
- Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Right and Human Welfare
- Issue: Vol 90, No 3 (2014)
- Pages: 95-104
- Section: CLINICAL PRACTICE GUIDELINES
- URL: https://ogarev-online.ru/0042-4609/article/view/116611
- DOI: https://doi.org/10.25208/0042-4609-2014-90-3-95-104
- ID: 116611
Cite item
Full Text
Abstract
Keywords
About the authors
M. R. Rakhmatulina
State Research Center of Dermatovenereology and Cosmetology, Ministry of healthcare of the Russian Federation
Author for correspondence.
Email: sanabol@mail.ru
Russian Federation
N. V. Bolshenko
Russian Medical Academy of Postgraduate Studies, Ministry of Health Russian Federation
Email: sanabol@mail.ru
Russian Federation
D. A. Kuevda
Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Right and Human Welfare
Email: sanabol@mail.ru
Russian Federation
O. B. Trofimova
Central Research Institute of Epidemiology, Russian Inspectorate for Protection of Consumer Right and Human Welfare
Email: sanabol@mail.ru
Russian Federation
References
- Kuznetsova Y.N., Evstigneyeva N.P., Oboskalova T.A. Complex therapy of clinical manifestations of urogenital papilloma-virus infection. Modern probl of dermatovenereol, immunol and med cosmetol 2009; 3 (6): 27-31
- Soloviyov A.M. Immunotherapy with isoprinosine as an adjuvant or independent method of treatment for patients with papilloma viral infection. Vestn dermatol i venerol 2011; 5: 146-151.
- Rahmatulina M.R. Experience of the combined therapy of anogenital (veneral) warts. Vestn dermatol i venerol 2012; 4: 105-110.
- Kaprin A.D. Zlokachestvennye novoobrazovaniya v Rossii v 2012 godu (zabolevaemost' i smertnost') / Pod redaktsiey A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoy. M: FGBU «MNIOI im. P.A. Gertsena» Minzdrava Rossii, 2014.
- Mayrand M-H., Duarte-Franco E., Rodrigues I. et al. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. New England Journal of Medicine 2007; 357: 1579-1588.
- Solomon D., Nayar R. The Bethesda System for reporting cervical cytology. Definition, criteria, and explanatory notes. Springer 2004; XXIII: 191.
- Minkina G.N., Shabalova I.P. Klassifikatsiya patologicheskikh izmeneniy sheyki matki. Morfologicheskaya terminologiya. Profilaktika raka sheyki matki. Rukovodstvo dlya vrachey pod redaktsiey G.T. Sukhikh. M: 2012. 38-45.
- Kitchener H.C., Peto J., Wheeler P. et al. ARTISTIC: a randomized train of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009 Nov; 13 (51): 1-150.
- Ronco G., Biggeri A., Confortini M. et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer. Epidemiol Prev 2012 May-Aug; 36 (3-4 Suppl): e1-72.
- Ronco G., Dillner J., Elfsröm K.M. et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four Europeen randomized controlled trials. The Lancet 2014 February; 383: 9916: 524-532.
- Pileggi C., Flotta D., Bianco A., et al. Is HPV DNA testing specificity comparable to that of cytological testing in primary cervical cancer screening? Results of a meta - analysis of randomized controlled trials. HYPERLINK "http:// www.ncbi.nlm.nih.gov/pubmed/?term=Is+HPv+ DNA+testing+specificity+comparable+to+that+o f+cytological+testing+in+primary+cervical+can cer+screening%3F+Results+of+a+meta+%E2% 80%93+analysis+of+randomized+controlled+tri als" o "International journal of cancer. Journal international du cancer." Int J Cancer 2014 Jul 1; 135 (1): 166-77.
- Kim J.J., Wright T.C., Goldie S.J. Cost - effectiveness of alternative triage studies for atypical squamous cells of undetermined significance. JAMA 2002; Vol. 287: 2382-2390.
- Kim J.J., Wright T.C., Goldie S.J. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France and Italy. Journal of the National Cancer Institute 2005; 97 (12): 888-895.
- Shipulina O.Yu. Algoritm diagnostiki virusa papillomy cheloveka. Spravochnik zaveduyushchego KDL 2010; 1: 3-11.
- World Health Organization (WHO). Comprehensive cervical cancer control: a guide to essential practice. Geneva, 2010
Supplementary files
